Turn Therapeutics Inc. (Nasdaq: TTRX) is a clinical-stage biotechnology company whose news flow centers on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. Company updates frequently highlight progress in its lead program GX-03, a topical IL-36/IL-31 pathway inhibitor in a phase 2 trial for moderate to severe atopic dermatitis, as well as other late-stage clinical programs in eczema and onychomycosis.
News releases from Turn Therapeutics regularly cover clinical milestones, such as enrollment updates, safety summaries, and timing for interim and topline data from its phase 2 eczema study. Investors and observers can also follow announcements related to its thermostable intranasal vaccine initiative, including stability data for a live, lipid-enveloped vaccine formulated with the PermaFusion platform and the planned in-vivo and in-vitro studies for an intranasal influenza vaccine candidate.
Corporate and strategic developments are another key theme in TTRX news. The company has reported its direct listing on Nasdaq, capital strategy using flexible financing arrangements, and a global supply, development, and license agreement with Medline to develop and commercialize PermaFusion-based products in professional and retail markets. Governance updates, including the appointments of experienced board members and a Vice President of Corporate Communications, also feature prominently.
Turn Therapeutics additionally issues communications on shareholder engagement efforts, such as webinar series and public discussions involving its leadership on topics like healthcare communication and public trust in science. For readers tracking TTRX, this news page offers a centralized view of clinical progress, partnership activity, financing developments, and corporate governance changes over time.
Turn Therapeutics (TTRX) will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET.
The presentation by CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will focus on the company’s atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and emerging findings across distinct patient populations. These include patients with moderate-severe baseline pruritus and a cohort with lower EASI scores but high investigator-assessed disease severity (IGA). A live webcast will be accessible via the Investors section of the Turn Therapeutics website, with a replay available for approximately six months.
Turn Therapeutics (TTRX) appointed Robert R. Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, as Chief Scientific Officer. He brings more than four decades of experience in immunology, microbiology, infectious disease, clinical research, and public health.
Dr. Redfield will help guide scientific and clinical strategy for GX-03 in atopic dermatitis, onychomycosis, hidradenitis suppurativa and potential additional indications, with a focus on cytokine signaling and host inflammatory responses. GX-03 is being evaluated in atopic dermatitis, where preclinical work showed effects on inflammatory mediators and interim data suggested strong efficacy and safety, and is also being developed for onychomycosis.
NovaBridge Biosciences (NBP) appointed Martin Dewhurst as an independent director on its Board on September 8, 2026.
Dewhurst will also serve on NovaBridge’s Audit Committee and Compensation Committee, effective immediately. He brings more than 30 years of leadership, governance, and strategic advisory experience across biotech, biopharma, medical devices, health tech, and healthcare investment, including over three decades at McKinsey & Company, where he co-led the Global Life Sciences Practice and co-founded the McKinsey Health Institute. His appointment follows the departure of independent director Liu Xin from the Board. Dewhurst currently holds multiple board and advisory roles in healthcare companies and investment firms.
Turn Therapeutics (Nasdaq:TTRX) reported new peer-reviewed in-vivo data showing its topical investigational therapy GX-03 selectively reduced key inflammatory cytokines and disease severity in a murine model of atopic dermatitis-like inflammation. The study in the journal Life evaluated 40 mice pretreated for four days with GX-03 or left untreated before standardized Staphylococcus aureus skin exposure. After exclusions, 18 animals per group were analyzed.
According to Turn Therapeutics, GX-03 pretreatment reduced mean vIGA-AD disease severity from 2.44 in untreated animals to 0.83, a 66.0% reduction. IL-36α fell by 49.9%, IL-36γ by 50.9%, IL-31 by 67.7%, and IL-4 by 16.7%, while IL-13 remained essentially unchanged, indicating a selective cytokine pattern. No local irritation, dryness, redness, barrier disruption or other adverse skin findings were reported during pretreatment. The study was conducted at Altogen Labs under an IACUC-approved protocol. GX-03 is being developed as a localized, non-systemic treatment for atopic dermatitis and is currently in a randomized, double-blind, vehicle-controlled clinical trial.
Turn Therapeutics (Nasdaq:TTRX) reported second quarter 2026 results and clinical updates for GX-03 in atopic dermatitis. An interim analysis of the ongoing Phase 2 trial, completed July 7, 2026, supported expanding Stage 2 enrollment to approximately 120–135 patients with moderate-to-severe lesions but broader disease extent.
According to Turn Therapeutics, GX-03 showed treatment separation from vehicle across four preselected efficacy endpoints, with up to 61.5% vs 8.3% achieving clear or almost clear skin at Week 4 and 46.2% vs 8.3% achieving EASI-100 at Week 8. Stage 1 showed no serious adverse events or discontinuations.
The company appointed former FDA Commissioner Stephen M. Hahn, M.D. as Executive Clinical and Regulatory Lead, published its first peer-reviewed preclinical GX-03 data, and plans a Phase 2a GX-03 study in hidradenitis suppurativa, targeting first patient dosing in Q2 2027.
Turn Therapeutics ended June 30, 2026 with $10.3 million in cash and cash equivalents and reported a Q2 2026 net loss of $5.85 million. The company estimates its cash will fund operations, including the Phase 2 atopic dermatitis trial, into the third quarter of 2027.
Turn Therapeutics (Nasdaq: TTRX) announced that Founder and CEO Bradley Burnam and members of the management team will ring the Nasdaq Closing Bell on Monday, August 10, 2026, at Nasdaq MarketSite in Times Square, New York, at Nasdaq's invitation to recognize the company's progress since its October 2025 direct listing.
The bell-ringing ceremony will be broadcast live beginning at 3:45 p.m. ET via Nasdaq's livestream. Turn Therapeutics is a clinical-stage biotechnology company developing targeted, localized, non-systemic therapies for inflammatory and infectious skin diseases. Its lead investigational topical candidate, GX-03, is being developed for atopic dermatitis and is designed to achieve biologic-level efficacy without injectable administration or systemic immunosuppression.
Turn Therapeutics (NASDAQ:TTRX) completed a comprehensive interim analysis of its adaptive Phase 2 trial of GX-03 in atopic dermatitis and finalized the Stage 2 design.
Data-supported changes include expansion to the full EASI severity spectrum, refined endpoints using the Hochberg procedure, and confirmation of a favorable safety and tolerability profile.
Turn Therapeutics (NASDAQ:TTRX) will host a live webcast on July 7, 2026, at 4:30 p.m. ET to present key findings from a comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis.
The company will also outline an optimized Stage 2 design guiding completion of the Phase 2 program. The review of Stage 1 data was overseen by Dr. Bruce Stouch and Dr. Stephen Hahn. CEO Bradley Burnam and Dr. Hahn will host the webcast, with replay access available.
Turn Therapeutics (Nasdaq:TTRX) reported interim Phase 2 GX-03 data in moderate-to-severe atopic dermatitis from the first 50 completed subjects. At Week 4, 92.6% of GX-03 patients achieved EASI-50 vs 65.2% on vehicle; EASI-90 was 44.4% vs 30.4%, rising to 51.9% vs 34.8% by Week 8.
No treatment-related serious adverse events, tolerability issues, or discontinuations were observed. Interim findings are being used to refine enrollment criteria, endpoint hierarchy, and focus on earlier inflammatory endpoints as enrollment nears the original target. The company is preparing FDA interactions on regulatory pathways.
Turn Therapeutics (Nasdaq:TTRX) reported a peer-reviewed publication in the Journal of Dermatological Treatment detailing GX-03 activity in an IL-36–associated Staphylococcus aureus-induced murine dermatitis model. GX-03 is the company’s lead program, currently in Phase 2 for moderate-to-severe atopic dermatitis.
Mice treated twice daily with GX-03 for seven days achieved a mean investigator global assessment score of 1.44 versus 3.00 in untreated controls (p = 0.0003), with no treatment-related adverse effects observed. The article is the first in a planned series exploring GX-03’s localized, non-systemic mechanism.